REPUBLIC OF LEBANON MINISTRY OF PUBLIC HEALTH Lebanon Clinical Trials Registry

CLDK378A2X01B Roll over study in patients with ALK postive malignancies

23/08/2025 04:45:25

Aain Information	
Primary registry identifying number	Protocol number
LBCTR2019010182	CLDK378A2X01B
MOH registration number 53628/2018	
Study registered at the country of origin	Study registered at the country of origin: Specify
Yes	
Type of registration	Type of registration: Justify
Prospective	N/A
Date of registration in national regulatory agency 27/12/2018	
Primary sponsor	Primary sponsor: Country of origin
Novartis Pharma Services Inc.	Novartis Pharmaceuticals
Date of registration in primary registry	Date of registration in national regulatory agency
13/08/2020	27/12/2018
Public title	Acronym
CLDK378A2X01B Roll over study in patients with ALK postive malignancies	
Scientific title	Acronym
An open-label, multi-center, Phase IV, roll-over study in patients with ALK positive malignancies who have completed a prior Novartis-sponsored ceritinib (LDK378) study and are judged by the investigator to benefit from continued treatment with ceritinib	
Brief summary of the study: English	
The rollover study will provide ceritinib to patients who are currently receiving treatment with ceritinib within a Novartis-sponsored study and in the opinion of the investigator, would benefit from continued treatment with ceritinib.	
Brief summary of the study: Arabic	
متعددة المراكز وتكميليّة لدى مرضى مصابين بأورام خبيثة إيجابيّة كيناز الورم اللمفي الكشمي والذين من مواصلة العلاج بسيريتينيب (LDK378) أنجزوا دراسة سابقة رعتها نوفارتيس حول سيريتينيب	
Health conditions/problem studied: Specify	
Non Small Cell Lung Cancer	
Interventions: Specify	
Drug : Ceritinib (Zykadia) capsules	
Key inclusion and exclusion criteria: Inclusion criteria	
 Patient is currently receiving treatment with ceritinib within a Novartis-spot objective and, in the opinion of the Investigator, would benefit from conti Patient has demonstrated compliance, as assessed by the investigator. 	inued treatment.

•Willingness and ability to comply with scheduled visits, treatment plans and any other study procedures.



REPUBLIC OF LEBANON MINISTRY OF PUBLIC HEALTH Lebanon Clinical Trials Registry

•Written informed consent obtained prior to enrolling in the roll-over study and receiving study medication. If consent cannot be expressed in writing, it must be formally documented and witnessed via an independent trusted witness.

Key inclusion and exclusion criteria: Specify gender
Key inclusion and exclusion criteria: Age maximum
99
+

Key inclusion and exclusion criteria: Exclusion criteria

Patient has been permanently and prematurely discontinued from ceritinib study treatment in the parent study due to any reason.
Patient currently has unresolved toxicities for which ceritinib dosing has been interrupted in the parent study.

•Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive serum hCG laboratory test.

•Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for 3 months afer stopping ceritinib treatment.

•Sexually active males unless they use a condom during intercourse while taking drug and for 3 months after stopping ceritinib and should not father a child for at least 3 months after the last dose of treatment.

Type of study

Interventional

Type of intervention Pharmaceutical	Type of intervention: Specify type N/A
Trial scope	Trial scope: Specify scope
Therapy	N/A
Study design: Allocation	Study design: Masking
N/A: Single arm study	Open (masking not used)
Study design: Control	Study phase
Active	4
Study design: Purpose	Study design: Specify purpose
Treatment	N/A
Study design: Assignment	Study design: Specify assignment
Single	N/A
IMP has market authorization	IMP has market authorization: Specify
Yes, Worldwide	Albania, Argentina, Canada, United states, United Arab Emirates, Ukraine, Turkey, Switzerland, Saudi Arabia, Oman, Mexico , Malasia
Name of IMP	Year of authorization Month of authorization
Zykadia	
Type of IMP	
Othere	

Others

Pharmaceutical class

Ceritinib is a potent adenosine triphosphate (ATP)-competitive inhibitor of ALK kinase activity.

Therapeutic indication

patients with ALK positive malignancies Non small cell Lung Cancer

Therapeutic benefit

- To collect safety data: adverse events and serious adverse events
- To evaluate clinical benefit as assessed by the investigator



REPUBLIC OF LEBANON Lebanon Clinical Trials Registry

Study model N/A Study model: Specify model N/A	Study model: Explain model N/A
Time perspective N/A Time perspective: Specify perspective N/A	Time perspective: Explain time perspective N/A
Target follow-up duration	Target follow-up duration: Unit
Number of groups/cohorts	
Biospecimen retention Samples without DNA	Biospecimen description Local Lab tests to follow up on patients safety. No samples will be shipped outside Lebanon
Target sample size 1 Date of first enrollment: Type Actual	Actual enrollment target size 1 Date of first enrollment: Date 26/03/2019
Date of study closure: Type Actual	Date of study closure: Date 18/11/2021
Recruitment status Complete	Recruitment status: Specify
Date of completion 26/03/2019	
IPD sharing statement plan No	IPD sharing statement description Not decided

Additional data URL https://clinicaltrials.gov/ct2/show/NCT02584933?term=CLDK378A2X01B&rank=1

Admin comments





Trial status

Approved

Secondary Identifying Numbers		
Full name of issuing authority	Secondary identifying number	
ClinicalTrials.gov	NCT02584933	
EUDRACT European Union Drug Regulating Authorities Clinical Trials	2015-001922-40	

Sources of Monetary or Material Support

Name

Novartis Pharma Services Inc.

Secondary Sponsors Name

Contact for Public/Scientific Queries						
Contact type	Contact full name	Address	Country	Telephone	Email	Affiliation
Public	Marwan Ghosn	Beirut	Lebanon	00961 1 613395	marwanghosnmd @yahoo.com	Hotel Dieu De France
Scientific	Hind Khairallah	Beirut	Lebanon	+961 1 512002 Ext. 271	Hind.Khairallah@ fattal.com.lb	Khalil Fattal et Fils s.a.l.

Centers/Hospitals Involved in the Study			
Center/Hospital name	/Hospital name Name of principles investigator Principles investigator Speciality Ethical approval		
Hotel Dieu De France	Dr Marwan Ghson	Hematology Oncology	Approved

Ethics Review				
Ethics approval obtained	Approval date	Contact name	Contact email	Contact phone
Hotel Dieu de France	05/12/2018	Marwan Ghosn	marwanghosnmd@yahoo.com	00961 1 613395

 \sim




Countries of Recruitment
Name
Lebanon
United States of America
Australia
Belgium
China
France
Germany
Italy
Russian Federation
Spain
Japan

Health Conditions or Problems Studied		
Condition Code Keyword		
Non Small Cell Lung Cancer	Malignant neoplasm of bronchus and lung (C34)	NSCLC

Interventions		
Intervention	Description	Keyword
Reference Table 7.1 of protocol	Informed consent / patient history / drug administration / Lab tests	ICF/ IMP administration/ Lab tests

Primary Outcomes		
Name	Time Points	Measure
1.Number of Participants with Adverse Events as a Measure of Safety and Tolerability	[Time Frame: Until no patients are left on study up to 5 years]	up to 5 years





Key Secondary Outcomes		
Name	Time Points	Measure
To evaluate clinical benefit as assessed by	Proportion of patients with clinical benefit	Confirmation of clinical benfit of study treament

Trial Results	
Summary results	
Study results globally	
Date of posting of results summaries	Date of first journal publication of results
Results URL link	
Baseline characteristics	
Participant flow	
Adverse events	
Outcome measures	
URL to protocol files	